Table II.
Comparisons performed and the relative DMRs found.
| Groups compared | Cases considered | Number of DMRs found | Hypomethylated DMRs, % | Hypermethylated DMRs, % | Number of DMRs associated with genes |
|---|---|---|---|---|---|
| 1: FBC vs. MBC (17 cases vs. 7 cases) | All cases | 2,846 | 67.83 | 32.17 | 2,486 |
| 2: FBC vs. MBC (10 cases vs. 6 cases) | BRCAX cases only | 1,242 | 93.56 | 6.44 | 1,102 |
| 3: BRCAX vs. BRCA1/2 (16 cases vs. 8 cases) | All cases | 364 | 46.70 | 53.30 | 357 |
| 4: BRCA1 vs. BRCA2 (4 cases vs. 3 cases) | Female cases only | 802 | 54.74 | 45.26 | 755 |
| 5: BRCA1 vs. BRCAX (4 cases vs. 10 cases) | Female cases only | 484 | 60.54 | 39.46 | 464 |
| 6: BRCA2 vs. BRCAX (3 cases vs. 10 cases) | Female cases only | 673 | 52.01 | 47.99 | 629 |
| 7: BRCA1 vs. BRCA2/X (4 cases vs. 13 cases) | Female cases only | 861 | 43.79 | 56.21 | 819 |
| 8: BRCA2 vs. BRCA1/X (4 cases vs. 14 cases) | Female cases only | 1,380 | 38.19 | 61.81 | 1,251 |
| 9: BRCAX vs. BRCA1/2 (10 cases vs. 7 cases) | Female cases only | 962 | 51.14 | 48.86 | 914 |
DMRs, differentially methylated regions; FBC, female breast cancer; MBC, male breast cancer.